By
Kyle Brasseur2024-01-18T19:40:00
The European Union moved closer to finalizing rules that would expand current anti-money laundering (AML) and customer due diligence (CDD) obligations to new sectors, in addition to granting greater powers to national financial intelligence units (FIUs).
On Thursday, European Parliament and the Council of the European Union finalized a rule package designed to enhance the EU’s toolkit to fight money laundering, terrorist financing, and sanctions evasion. The deal will next move to formal adoption before its changes enter force.
The changes correspond with the provisional approval last month of the creation of a new agency, the Anti-Money Laundering Authority, to supervise high-risk financial institutions across the European Union regarding their AML and countering the financing of terrorism activities.
2024-01-17T22:45:00Z By Aaron Nicodemus
A survey of financial crime professionals found that while three of every four companies added more anti-money laundering employees in 2023, nearly all respondents said growing their department’s headcount alone won’t keep up with emerging risks.
2024-01-17T12:25:00Z By Ruth Prickett
The impact of the Anti-Money Laundering Authority to improve the coordination and success of AML activities will be largely indirect, depending on its influence over European national governments continuing to supervise most EU financial services firms.
2023-12-14T15:42:00Z By Kyle Brasseur
A new agency to supervise high-risk financial institutions across the European Union regarding their anti-money laundering and countering the financing of terrorism activities gained provisional approval.
2025-12-10T15:30:00Z By Neil Hodge
For the past decade, Europe has led in creating strong but flexible rules for data use and safe AI development. The EU’s new plans to simplify key data privacy and AI governance measures have received a mixed response.
2025-12-05T19:25:00Z By Oscar Gonzalez
The U.S. Securities and Exchange Commission’s (SEC) Division of Examinations released its 2026 examination priorities, which give companies a roadmap of areas of heightened risk and regulatory focus for next year.
2025-12-04T22:15:00Z By Ruth Prickett
Regulation is a matter of life and death in the pharmaceutical industry. Rules to combat practices that can kill have been in force for decades, but tech developments are rapidly creating new risks and focusing lawmakers’ attention on areas where some compliance teams may lack experience.
Site powered by Webvision Cloud